Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: enoticumab, demcizumab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 1,375 | 0.91 |
| pathways Reactome | 10 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 15201
Sealed predictions
- DLL4 in dopamine neurons, braak-0.55 (p 0.123) → -0.21 (p 0.591)receipt 15208
Swarm cases
receipt 15208: DLL4 in dopamine neurons, braak
- power
- full sample -0.40 (p 0.097, n 18), 95% CI -0.73 to +0.08. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.38 (p 0.123, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.56 (p 0.015, n 18). not the mix.
- skeptic
- leave-one-out range -0.54 to -0.32, sign flips 0; without severely affected donors -0.40 (p 0.097, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DLL4 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts